AFL · 10-Q · 2026Q2 · Full report

Aflac Japan Sales Trends

AFLAC INC · 2026-08-07 · Importance 25 · Surprise 48 · Matches filing data

Aflac Japan’s new annualized premium sales decreased 14.3% in yen terms in the second quarter of 2026, primarily because the prior-year period benefited from the March 2025 launch of Miraito cancer insurance. For the first six months, sales increased 23.2% in yen terms, driven by strong demand for the refreshed Tsumitasu savings-type life insurance product and Anshin Palette medical insurance, launched in December 2025. Cancer products remained the largest contributor, representing 54.7% of six-month sales, while Tsumitasu contributed 19.2% and medical and other health products contributed 20.5%. Aflac expects continued demand for third-sector cancer and medical products as pressure on Japan’s health care system increases, while first-sector products may support younger-customer acquisition and cross-selling.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuenegativerealized-24.3%Annualized premiums in force translated into U.S. dollars were $7.2 billion at June 30, 2026, compared with $8.2 billion at June 30, 2025.